Cargando…

What do we know about managing Dupuytren’s disease cost-effectively?

BACKGROUND: Dupuytren’s disease (DD) is a common and progressive, fibroproliferative disorder of the palmar and digital fascia of the hand. Various treatments have been recommended for advanced disease or to retard progression of early disease and to prevent deterioration of the finger contracture a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dritsaki, Melina, Rivero-Arias, Oliver, Gray, Alastair, Ball, Catherine, Nanchahal, Jagdeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785840/ https://www.ncbi.nlm.nih.gov/pubmed/29370792 http://dx.doi.org/10.1186/s12891-018-1949-2

Ejemplares similares

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)
por: Png, May Ee, et al.
Publicado: (2019)

Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model
por: Dakin, Helen, et al.
Publicado: (2022)

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.
por: Nanchahal, Jagdeep, et al.
Publicado: (2017)

Recent advances in the understanding of Dupuytren’s disease
por: Layton, Thomas, et al.
Publicado: (2019)

Systematic review of non-surgical treatments for early dupuytren’s disease
por: Ball, Catherine, et al.
Publicado: (2016)

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice
por: Ball, Catherine, et al.
Publicado: (2013)

Treatments for early-stage Dupuytren’s disease: an evidence-based approach
por: Nanchahal, Jagdeep, et al.
Publicado: (2023)

What do we know about neutrinos?
por: Vannucci, François
Publicado: (1994)

What do we know about pseudodementia?
por: Mouta, Salomé, et al.
Publicado: (2023)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Q&A: What do we know about influenza and what can we do about it?
por: Doherty, Peter C, et al.
Publicado: (2009)

What We Know and Do Not Know about Sex and Cardiac Disease
por: Konhilas, John P.
Publicado: (2010)

What Do We Know About Youth Softball Pitching and Injury?
por: Barfield, Jeff, et al.
Publicado: (2018)

Dupuytren's disease: what dermatologists need to know
por: Amadio, Camila Ribeiro, et al.
Publicado: (2018)

What do we know about the Higgs boson ?
por: Gambino, Paulo
Publicado: (2002)

What do We Know about Neonatal Cognition?
por: Streri, Arlette, et al.
Publicado: (2013)

What Do We Know about Opioids and the Kidney?
por: Mallappallil, Mary, et al.
Publicado: (2017)

What do we know about Tietze’s syndrome?
por: Rokicki, Wojciech, et al.
Publicado: (2018)

What Do We Know about Nociplastic Pain?
por: Bułdyś, Kacper, et al.
Publicado: (2023)

Neuropathic pain; what we know and what we should do about it
por: Smith, Peter A.
Publicado: (2023)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Transcranial Electrical Stimulation: What We Know and Do Not Know About Mechanisms
por: Fertonani, Anna, et al.
Publicado: (2016)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Secrets of platelet exocytosis – what do we really know about platelet secretion mechanisms?
por: Golebiewska, Ewelina M, et al.
Publicado: (2014)

Arterial Stiffness—What Do We Know about It and What Do We Expect from This Biomarker?
por: Reiner, Željko
Publicado: (2022)

What Do We Know About Neuropsychological Aspects Of Schizophrenia?
por: Palmer, Barton W., et al.
Publicado: (2009)

What do we know about $\sigma$?: summary of the session
por: Montanet, Lucien
Publicado: (1999)

What Do We Really Know About Neutron Stars?
por: Woltjer, Lodewijk
Publicado: (2003)

Fungal Melanin: What do We Know About Structure?
por: Nosanchuk, Joshua D., et al.
Publicado: (2015)

What we do not know about cerebellar systems neuroscience
por: Voogd, Jan
Publicado: (2014)

Targeting Microbiota: What Do We Know about It at Present?
por: Derovs, Aleksejs, et al.
Publicado: (2019)

What do we know about pediatric renal microlithiasis?
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2016)

What Do We Know About Remdesivir Drug Interactions?
por: Yang, Katherine
Publicado: (2020)

What we know but do not understand about nidovirus helicases
por: Lehmann, Kathleen C., et al.
Publicado: (2015)

What do we know about the microbiome of I. ricinus?
por: Hodosi, Richard, et al.
Publicado: (2022)

What Do We Know about Barley miRNAs?
por: Volná, Adriana, et al.
Publicado: (2022)

Suicide among physicians: what do we know about it?
por: Vaz, R. P., et al.
Publicado: (2023)

What do we know about lithium associated hypercalcemia?
por: Laherrán Cantera, N., et al.
Publicado: (2023)

What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries
por: Portnoy, Allison, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_91a06nvg1fcgopl7o61josv1mq